Berotralstat Crystalline Dihydrochloride Patent Information
The synthesis of berotralstat crystalline dihydrochloride is protected by several patents. These patents cover different aspects of the drug's manufacturing process, including specific crystalline forms and synthesis routes.
When Does the Berotralstat Dihydrochloride Patent Expire?
The primary patents protecting berotralstat crystalline dihydrochloride are expected to expire in the coming years. For detailed information on specific patent expiration dates and their implications for market entry, resources like DrugPatentWatch.com can provide comprehensive data [1].
What Are the Key Patents for Berotralstat Synthesis?
Several patents are relevant to the synthesis of berotralstat crystalline dihydrochloride. These include patents that claim specific polymorphic forms of the drug, which can affect its stability, bioavailability, and manufacturing ease. Other patents may cover novel synthesis pathways that offer advantages in terms of yield, purity, or cost-effectiveness [1].
Who Owns the Berotralstat Patents?
The patents for berotralstat and its crystalline dihydrochloride form are held by BioCryst Pharmaceuticals, Inc. [2].
How Are Berotralstat Patents Being Challenged?
While specific details on current patent challenges for berotralstat crystalline dihydrochloride are not provided, pharmaceutical companies often engage in patent litigation to invalidate existing patents or to clear the way for generic competition [1]. Challenges can arise from companies seeking to produce biosimilar or generic versions of the drug.
What Are the Implications of Patent Expiry for Berotralstat?
Upon the expiry of key patents, generic manufacturers may be able to enter the market with their own versions of berotralstat. This typically leads to increased competition and potentially lower drug prices for patients and healthcare systems [1].
What is Berotralstat Used For?
Berotralstat is a medication approved for the prophylactic treatment of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older [3]. It works by inhibiting the enzyme plasma kallikrein, a key factor in HAE attacks [4].
What Is the Mechanism of Action for Berotralstat?
Berotralstat is an orally administered, once-daily plasma kallikrein inhibitor [3]. By inhibiting plasma kallikrein, it reduces the production of bradykinin, a peptide that is overproduced in HAE and causes swelling, pain, and other symptoms [4].
What Are the Clinical Trial Results for Berotralstat?
Clinical trials have demonstrated that berotralstat significantly reduces the monthly attack rate of HAE compared to placebo [3]. Studies have shown a statistically significant reduction in HAE attack frequency in patients treated with berotralstat [4].
What Are the Side Effects of Berotralstat?
Common side effects reported in clinical trials include gastrointestinal issues such as diarrhea, nausea, vomiting, and abdominal pain [3].
How Does Berotralstat Compare to Other HAE Treatments?
Berotralstat offers an oral, once-daily treatment option for HAE prophylaxis [3]. Other treatments for HAE may involve subcutaneous or intravenous injections, or different mechanisms of action [4].
What is the Dosage and Administration of Berotralstat?
Berotralstat is taken orally, once daily, with or without food [3]. The typical dosage for adults and pediatric patients 12 years and older is 110 mg [3].
---
Sources:
[1] DrugPatentWatch.com
[2] BioCryst Pharmaceuticals, Inc.
[3] FDA approval information for berotralstat (Orladeyo)
[4] Medical literature on hereditary angioedema treatments